Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke

Omecamtiv mecarbil (OM) is a positive cardiac inotrope in phase-3 clinical trials for treatment of heart failure. Although initially described as a direct myosin activator, subsequent studies are at odds with this description and do not explain OM-mediated increases in cardiac performance. Here we s...

Descripción completa

Detalles Bibliográficos
Autores principales: Woody, Michael S., Greenberg, Michael J., Barua, Bipasha, Winkelmann, Donald A., Goldman, Yale E., Ostap, E. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155018/
https://www.ncbi.nlm.nih.gov/pubmed/30242219
http://dx.doi.org/10.1038/s41467-018-06193-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155018/
https://www.ncbi.nlm.nih.gov/pubmed/30242219
http://dx.doi.org/10.1038/s41467-018-06193-2

Ejemplares similares